Evidence map›Paper›PMID 37122395›Full record

ArticleInternational journal of clinical practice2023

What Is the Place of Intermediate Care Unit in Patients with COVID-19? A Single Center Experience.

Hale Bülbül, Gözde Derviş Hakim, Cengiz Ceylan, Murat Aysin, Şükran Köse

Open access · goldAbstract read
In one paragraph

Article in International journal of clinical practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Observational
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Hale BülbülHematology Department, Health Sciences University İzmir Medicine Faculty, Tepecik Training and Research Hospital, Yenişehir, Konak, İzmir, Turkey.ORCID https://orcid.org/0000-0001-5333-8679
Gözde Derviş HakimGastroenterology Department, Health Sciences University İzmir Medicine Faculty, Tepecik Training and Research Hospital, Yenişehir, Konak, İzmir, Turkey.ORCID https://orcid.org/0000-0001-9676-9532
Cengiz CeylanHematology Department, Health Sciences University İzmir Medicine Faculty, Tepecik Training and Research Hospital, Yenişehir, Konak, İzmir, Turkey.ORCID https://orcid.org/0000-0003-3471-8726
Murat AysinPublic Health Department, İzmir Katip Çelebi University Atatürk Training and Research Hospital, Karabağlar, İzmir, Turkey.ORCID https://orcid.org/0000-0003-4068-5860
Şükran KöseInfectious Diseases Department, Health Sciences University İzmir Medicine Faculty, Tepecik Training and Research Hospital, Yenişehir, Konak, İzmir, Turkey.ORCID https://orcid.org/0000-0002-4228-1213
Yenişehir Hospital · TRIzmir Kâtip Çelebi University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: COVID-19 pandemic has led to an increased rate of intensive care unit (ICU) stays. Intermediate care units (IMCUs) are a useful resource for the management of patients with severe COVID-19 that do not require ICU admission. In this research, we aimed to determine survival outcomes and parameters predicting mortality in patients who have been admitted to IMCU. Materials and Methods: Patients who were admitted to IMCU between April 2019 and January 2021 were analyzed retrospectively. Sociodemographics, clinical characteristics, and blood parameters on admission were compared between the patients who died in IMCU and the others. Blood parameters at discharge were compared between survived and deceased individuals. Survival analysis was performed via Kaplan-Meier analysis. Blood parameters predicting mortality were determined by univariate and multivariate Cox regression analysis. Results: A total of 140 patients were included within the scope of this study. The median age was 72.5 years, and 77 (55%) of them were male and 63 (45%) of them were female. A total of 37 (26.4%) patients deceased in IMCU, and 40 patients (28.5%) were transferred to ICU. Higher platelet count (HR 3.454; 95% CI 1.383-8.625; Conclusions: IMCU seems to have a positive effect on survival in patients with severe COVID-19 infection. Close monitoring of these parameters and early intervention may improve survival rates and outcomes.

Indexed as

COVID-19Intensive Care UnitsAgedFemaleHumansIntermediate Care FacilitiesMalePandemicsProcalcitoninRetrospective StudiesProcalcitonin

Identifiers

PMID37122395
PMCPMC10139809
OpenAlexW4366548033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.